| Name | Title | Contact Details |
|---|
Our founding belief is that the future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. Today, the molecular world of the cell can be experimentally interrogated like never before. The resulting datasets provide an unprecedented opportunity to build artificial intelligence systems that are biologically accurate and that support the detection of disease and the development of molecular interventions. Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. Over the next two years, Deep Genomics will use its platform to unlock new classes of antisense oligonucleotide therapies that were previously inaccessible or out of reach, and advance them for clinical evaluation. In project Saturn, the platform will be used to search across a vast space of over 69 billion molecules with the goal of generating a library of 1000 compounds that can be used to manipulate cell biology and design therapies.
Iomai Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.
Afrivax is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics.